12 results about "GABA receptor" patented technology

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.

In some embodiments, a composition comprising Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus plantarum, and Streptococcus thermophilus is provided. In some embodiments, provided is the use of a composition of any of the examples herein for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorder (ASD), anxiety disorder and / or gastrointestinal (GI) disorder or condition, enhancing attention and / or concentration, or stimulating a GABA receptor in a subject. In some embodiments, methods and kits are provided for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorders, anxiety disorders, and / or gastrointestinal disorders or conditions, enhancing attention and / or concentration, or stimulating GABA receptors in a subject. In certain embodiments, the compositions are safe to use and effective to prevent or alleviate anxiety and / or sensory hypersensitivity in subjects, particularly children subjects.

The present invention relates to a synergistic composition for the treatment of disorders related to central nervous system (CNS) excitability. The synergistic composition comprises combination of GABA receptor agonists and synaptic plasticity enhancer or salts thereof along with pharmaceutically acceptable excipients. The GABA receptor agonists are selected from the group consisting of 4-[(2R)-2,4-Dihydroxy-3,3-dimethylbutanamido]butanoic acid, 4- (Pyridine-3-carbonylamino)butanoic acid and 4-(hexadecanoylamino)butanoic acid or salts thereof. The synaptic plasticity enhancer are selected from magnesium 2- acetamidoethanesulfonate, magnesium bis (2-aminoethane-1-sulfonate), magnesium;(2S,3R)- 2,3,4-trihydroxybutanoate, N-(2-Hydroxyethyl)hexadecanamide, 1-(4-aminobutyl)guanidine and 5'-inosinic acid or salts thereof.

The invention discloses a dampness-clearing sleep-aiding Tibetan foot bathing tablet and a preparation method thereof, and relates to the technical field of traditional Chinese medicine preparations, the dampness-clearing sleep-aiding Tibetan foot bathing tablet is composed of a monarch drug group, a ministerial drug group, an adjuvant drug group, a conductant drug group and an auxiliary material group, and the preparation method comprises the following steps: step 1, crushing; step 2, weighing; step 3, extracting active ingredients; step 4, drying and powdering; step 5, total mixing; step 6, tabletting; step 7, inner packaging; and step 8, external packaging. Through the compatibility of monarch, minister, assistant and guide, the synergistic effect of dampness clearing and sleep aiding is realized, the monarch drug group and the adjuvant drug group synergistically regulate a dampness clearing pathway (AQP4 aquaporin + TRPV1 ion channel), the minister drug group and the guide drug group synergistically enhance the sleep aiding effect (GABA receptor activation + glutamic acid inhibition), and clinical experiments show that after the traditional Chinese medicine composition is used for 4 weeks, the effective rate of improving the dampness symptom reaches 80%, and the curative effect is good. And the sleep quality improvement rate reaches 82%.

The present application provides a propofol analogue, a preparation method thereof and application thereof in non-narcotic field. The propofol analogue has a structure as shown in general formula (G). The propofol analogue of the present application can greatly reduce or eliminate the affinity to GABA receptor, i.e. weaken or eliminate the narcotic property. It targets specific targets and shows effects in improving sleep, regulating blood pressure, relieving vomiting, resisting depression, protecting heart and brain, etc. (G).

The invention discloses an essential oil composition as well as a preparation method and application thereof. The composition comprises jasmine essential oil, torreya grandis essential oil and basil essential oil. The essential oil composition disclosed by the invention can induce the expression of sleep-related genes Gabra1 and Htr1a and promote sleep by improving the expression of a 5-HT receptor and a GABA receptor.

This invention relates to the field of traditional Chinese medicine technology, and more particularly to a Jin medicine compound calming ointment that prolongs deep sleep and is non-addictive, as well as its preparation method. This invention is the first to use prolonging deep sleep duration as the core therapeutic target. The combined use of various herbs in this invention nourishes blood and calms the mind, nourishes yin and clears heat, and harmonizes the heart and kidneys, effectively treating insomnia caused by deficiency of heart and liver blood, disharmony between heart and kidneys, and yin deficiency with excessive fire. Furthermore, this invention, through the synergistic effect of multiple components, can effectively regulate the neurotransmitter GABA receptors, targeting and prolonging deep sleep, reducing the number of nighttime awakenings, fundamentally optimizing sleep structure, and also inhibiting excessive activation of the HPA axis, reducing abnormally elevated cortisol levels, thereby alleviating anxiety, breaking the vicious cycle of anxiety-insomnia, and effectively treating anxiety-related insomnia. Simultaneously, it has antioxidant effects, protects nerve cells, improves cerebral microcirculation, provides sufficient oxygen and nutrients to the brain, and creates a favorable physiological environment for the restoration of normal sleep rhythms.

The invention relates to the technical field of food, and particularly discloses a composition for promoting auditory sense system development and application. The composition is prepared from the following components in parts by mass: 0.1 part of IGF-1 and 1 to 1500 parts of structural triglyceride. A specific amount of IGF-1 is compounded with structural triglyceride, so that the movement speed and average movement distance of the zebrafish after auditory stimulation can be increased, the content of 5-hydroxytryptamine and acetylcholin esterase in the zebrafish is increased, the expression of GABA receptor genes is promoted, and the yield of the zebrafish is increased. By adding important neurotransmitters in an auditory sense system, auditory sense neuron survival, differentiation and synaptic formation are supported, so that the excitability of an auditory sense nerve pathway is adjusted, and the development of the auditory sense system is promoted. The composition can be used for preparing food such as infant formula milk powder, child formula milk powder, liquid milk, infant complementary food, supplements or dietary supplements.

The invention discloses application of 2-hydroxy-4-(2-hydroxy-3, 5-dichlorobenzyl) aminobenzoic acid 2-borneol ester in treatment of mental diseases, belongs to the field of pharmacy, and provides a novel medicine for treating mental diseases. Excitation / inhibition unbalance of a nerve circuit can be adjusted through mechanisms such as nNOS-PSD95 uncoupling and alpha2GABAA receptor agonistic action, and an obvious inhibition effect on immune inflammation which has an important position in occurrence and development of mental diseases is achieved. In consideration of complex causes of mental diseases and difficulty in good treatment effect of single-target mechanism medicines, the novel medicine provided by the invention further inhibits central inflammation on the basis of regulating excitation / inhibition imbalance of a central nervous circuit, comprehensively aims at various etiological mechanisms of the mental diseases, is remarkably different from an existing treatment medicine mechanism, and has a good application prospect. The traditional Chinese medicine has the advantages of remarkable treatment effect, quick response, small side effect, no response to the existing medicine and the like.

The application discloses a woodfordioid toxic alkane type sesquiterpene CNA, a preparation method and application thereof, and belongs to the field of traditional Chinese medicine pharmacy. The woodfordioid toxic alkane type sesquiterpene CNA compound of formula I is obtained by cold soaking, silica gel and gel column chromatography from Artocarpus styracifolius. The CNA compound has a new cis-hydrogenated indene core structure, contains nine continuous chiral centers and a highly crowded polycyclic skeleton feature, and has good biological activity. Cell experiments show that the woodfordioid toxic alkane type sesquiterpene CNA has signal transmission to endogenous and exogenous system GABA B receptor and can be used for preparing drugs for treating or preventing nervous system related diseases, and opens up a new direction for developing a new GABA B receptor antagonist or modulator and exploring a GABA receptor related treatment target and developing a nervous system disease drug.

A pharmaceutical composition is provided and includes at least one orthosteric GABA receptor ligand that directly binds to at least one GABA-A receptor or at least one GABA-B receptor at the endogenous GABA binding site, and at least one non-orthosteric GABA receptor ligand that binds a site distinct from the endogenous GABA binding site on at least one GABA receptor type. This ensures the orthosteric and non-orthosteric ligands for each receptor type are co-present. The orthosteric and non-orthosteric ligands may be co-formulated for concurrent availability, such that the presence of the orthosteric ligand enables or enhances the therapeutic effect of the non-orthosteric ligand.

A pharmaceutical composition is provided and includes at least one orthosteric GABA receptor ligand that directly binds to at least one GABA-A receptor or at least one GABA-B receptor at the endogenous GABA binding site, and at least one non-orthosteric GABA receptor ligand that binds a site distinct from the endogenous GABA binding site on at least one GABA receptor type. This ensures the orthosteric and non-orthosteric ligands for each receptor type are co-present. The orthosteric and non-orthosteric ligands may be co-formulated for concurrent availability, such that the presence of the orthosteric ligand enables or enhances the therapeutic effect of the non-orthosteric ligand.